| NDC Code | 0006-5033-02 |
|---|
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-5033-02) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (0006-5033-01) |
|---|
| Product NDC | 0006-5033 |
|---|
| Product Type Name | HUMAN PRESCRIPTION DRUG |
|---|
| Proprietary Name | Ontruzant |
|---|
| Non-Proprietary Name | Trastuzumab |
|---|
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
|---|
| Usage | INTRAVENOUS |
|---|
| Start Marketing Date | 20200415 |
|---|
| End Marketing Date | 20230930 |
|---|
| Marketing Category Name | BLA |
|---|
| Application Number | BLA761100 |
|---|
| Manufacturer | Merck Sharp & Dohme Corp. |
|---|
| Substance Name | TRASTUZUMAB |
|---|
| Strength | 150 |
|---|
| Strength Unit | mg/1 |
|---|
| Pharmacy Classes | HER2/Neu/cerbB2 Antagonists [MoA], HER2/neu Receptor Antagonist [EPC] |
|---|